Radioembolization Practice in North America Versus Europe: Results from a Global Survey

Purpose: The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) conducted an international survey on the real-life application of transarterial radioembolization (TARE). This sub-analysis of the complete survey evaluates intercontinental disparities in TARE practices. Materials and Methods: A survey of 32 multiple-choice questions was distributed to CIRSE members between November and December 2022. The questions addressed steps of the TARE workflow, including treatment work-up, planning and dosimetry, intervention, follow-up and innovations. Responses were curated to remove duplicates and incomplete entries and categorised into continental groups. Analysis focused on variations between Europe and North America and impacting factors in the respective regions were identified. Data is presented using descriptive statistics. Results: Responses were obtained from 30 countries and 133 hospitals, including 87 European and 21 North American centres. Hepatocellular carcinoma was the most common indication, constituting 61% of treatments in North America and 51% in Europe. North America predominantly used 90Y glass microspheres, whereas Europe used 90Y resin. Procedural differences included the adoption of intra-procedural CT imaging, utilized by all North American sites, versus 89% of European sites. Outpatient treatments were favoured in North America (85%), while in Europe, most patients remained hospitalized for one night (51%). Both regions increasingly emphasized dosimetry-guided treatments, with personalized dosimetry planning in 71% and 84% of North American and European sites, respectively. Conclusions: This North America–Europe comparison highlights regional differences in radioembolization practice between the leading continents in procedure volume, based on results of the CIRSE TARE survey. Specific intercontinental differences identified in this survey included hospitalization, product utilization, and procedural techniques.

Authors

Institutions

Publication Details

Journal
Current Oncology
Published
2026-05-12
DOI
https://doi.org/10.3390/curroncol33050285
Primary Topic
Hepatocellular Carcinoma Treatment and Prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Radioembolization Practice in North America Versus Europe: Results from a Global Survey

G. Keane, Marnix G. E. H. Lam, Maarten L. J. Smits, Hugo W. A. M. de Jong et al.
Current Oncology
Hepatocellular Carcinoma Treatment and Prognosis
article

Radioembolization Practice in North America Versus Europe: Results from a Global Survey

G. Keane, Marnix G. E. H. Lam, Maarten L. J. Smits, Hugo W. A. M. de Jong, Nathalie Kaufmann, Arthur J. A. T. Braat, Rutger C. G. Bruijnen, Riad Salem
article en

Abstract

Purpose: The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) conducted an international survey on the real-life application of transarterial radioembolization (TARE). This sub-analysis of the complete survey evaluates intercontinental disparities in TARE practices. Materials and Methods: A survey of 32 multiple-choice questions was distributed to CIRSE members between November and December 2022. The questions addressed steps of the TARE workflow, including treatment work-up, planning and dosimetry, intervention, follow-up and innovations. Responses were curated to remove duplicates and incomplete entries and categorised into continental groups. Analysis focused on variations between Europe and North America and impacting factors in the respective regions were identified. Data is presented using descriptive statistics. Results: Responses were obtained from 30 countries and 133 hospitals, including 87 European and 21 North American centres. Hepatocellular carcinoma was the most common indication, constituting 61% of treatments in North America and 51% in Europe. North America predominantly used 90Y glass microspheres, whereas Europe used 90Y resin. Procedural differences included the adoption of intra-procedural CT imaging, utilized by all North American sites, versus 89% of European sites. Outpatient treatments were favoured in North America (85%), while in Europe, most patients remained hospitalized for one night (51%). Both regions increasingly emphasized dosimetry-guided treatments, with personalized dosimetry planning in 71% and 84% of North American and European sites, respectively. Conclusions: This North America–Europe comparison highlights regional differences in radioembolization practice between the leading continents in procedure volume, based on results of the CIRSE TARE survey. Specific intercontinental differences identified in this survey included hospitalization, product utilization, and procedural techniques.

Current OncologyVol. 33(5)
Northwestern University (US), The Netherlands Cancer Institute (NL), Boston Scientific (United States) (US), University Medical Center Utrecht (NL), Clinical Research Organization (BD), Northwestern Medicine (US), Cardiovascular and Interventional Radiological Society of Europe (AT)
Openalex Percentile: Top 7%
Hepatocellular Carcinoma Treatment and Prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.